Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

NCT02564523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1075

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemorrhagic Fever, Ebola

Interventions

BIOLOGICAL: Ad26.ZEBOV
BIOLOGICAL: MVA-BN-Filo
BIOLOGICAL: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.

Collaborators

[object Object]
[object Object]
[object Object]